

Oklahoma Health Care Authority

Drug Utilization Review Board

(DUR Board)

Meeting – June 14, 2023 @ 4:00pm

at the

Oklahoma Health Care Authority (OHCA)

4345 N. Lincoln Blvd.

Oklahoma City, Oklahoma 73105

NOTE: *The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.*

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

A. Roll Call – Dr. Wilcox

DUR Board Members:

Dr. Jennifer de los Angeles –	participating in person
Mr. Kenneth Foster –	participating in person
Dr. Megan Hanner –	participating in person
Dr. Lynn Mitchell –	participating in person
Dr. John Muchmore –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person
Dr. Edna Patatanian –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:

https://zoom.us/webinar/register/WN_73z8ERX7Sv-KeQGP3GVqPg

After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:

Dial: +1-602-753-0140 or +1-669-219-2599

Webinar ID: 952 7560 1667

Passcode: 69395211

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the [Speaker Registration Form](#). Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. April 12, 2023 DUR Board Meeting Minutes
- B. April 12, 2023 DUR Board Recommendations Memorandum

Items to be presented by Dr. Reynolds, Dr. Kottoor, Dr. Muchmore, Chairman:

4. Update on Medication Coverage Authorization Unit/Opioid Utilization and the SoonerCare Morphine Milligram Equivalent (MME) Limit – See Appendix B

- A. Pharmacy Help Desk Activity for April 2023
- B. Medication Coverage Activity for April 2023
- C. Pharmacy Help Desk Activity for May 2023
- D. Medication Coverage Activity for May 2023
- E. Opioid Utilization and the SoonerCare Morphine Milligram Equivalent (MME) Limit

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Brenzavvy™ (Bexagliflozin), Mounjaro® (Tirzepatide), and Tzield™ (Teplizumab-mzvw) and Update the Approval Criteria for the Anti-Diabetic Medications and Kerendia® (Finerenone) – See Appendix C

- A. Market News and Updates
- B. Product Summaries

C. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Syfovre™ (Pegcetacoplan) – See Appendix D

- A. Introduction
- B. Syfovre™ (Pegcetacoplan) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Reynolds, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Ancobon® (Flucytosine) and Vivjoa® (Oteseconazole) and Update the Approval Criteria for the Systemic Antifungal Medications – See Appendix E

- A. Market News and Updates
- B. Vivjoa® (Oteseconazole) Product Summary
- C. Cost Comparison: Recurrent Vulvovaginal Candidiasis (RVVC) Treatments
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Kottoor, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Doral® (Quazepam) – See Appendix F

- A. Market News and Updates
- B. Doral® (Quazepam) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

9. Action Item – Vote to Prior Authorize Konvomep™ (Omeprazole/Sodium Bicarbonate for Oral Suspension) and Update the Approval Criteria for the Anti-Ulcer Medications – See Appendix G

- A. Market News and Updates
- B. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

10. Action Item – Vote to Prior Authorize Skyclarys™ (Omaveloxolone) – See Appendix H

- A. Skyclarys™ (Omaveloxolone) Product Summary
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

11. Action Item – Vote to Prior Authorize Filspari™ (Sparsentan) – See Appendix I

- A. Introduction
- B. Filspari™ (Sparsentan) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

12. Action Item – Vote to Prior Authorize Imjudo® (Tremelimumab) and Krazati® (Adagrasib) and Update the Approval Criteria for the Lung Cancer Medications – See Appendix J

- A. Market News and Updates
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

13. Annual Review of Genitourinary and Gynecologic Cancer Medications and 30-Day Notice to Prior Authorize Adstiladrin® (Nadofaragene Firadenovaccng) and Elahere™ (Mirvetuximab Soravtansine-gynx) – See Appendix K

- A. Current Prior Authorization Criteria
- B. Utilization of Genitourinary and Gynecologic Cancer Medications
- C. Prior Authorization of Genitourinary and Gynecologic Cancer Medications
- D. Market News and Updates
- E. Product Summaries
- F. College of Pharmacy Recommendations
- G. Utilization Details of Genitourinary and Gynecologic Cancer Medications

Items to be presented by Dr. Kottoor, Dr. Muchmore, Chairman:

14. Annual Review of the SoonerCare Pharmacy Benefit – See Appendix L

- A. Summary
- B. Medicaid Drug Rebate Program
- C. Alternative Payment Models
- D. Drug Approval Trends
- E. Traditional versus Specialty Pharmacy Products
- F. Top 10 Traditional Therapeutic Classes by Reimbursement
- G. Top 10 Specialty Therapeutic Classes by Reimbursement
- H. Top 10 Medications by Reimbursement
- I. Cost per Claim
- J. Market Projections
- K. Conclusion

Items to be presented by Dr. Ratterman, Dr. Muchmore, Chairman:

15. Annual Review of Hemophilia Medications and 30-Day Notice to Prior Authorize Altuviiio™ [Antihemophilic Factor (Recombinant), Fc-VMF-XTEN Fusion Protein-ehtl] and Hemgenix® (Etranacogene Dezaparvovec-drlb) – See Appendix M

- A. Current Prior Authorization Criteria
- B. Utilization of Hemophilia Medications
- C. Prior Authorization of Hemophilia Medications
- D. Market News and Updates
- E. Product Summaries
- F. OHCA Recommendations

G. Utilization Details of Hemophilia Medications

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

16. Annual Review of Attention-Deficit/Hyperactivity Disorder (ADHD) and Narcolepsy Medications and 30-Day Notice to Prior Authorize Lamryz™ (Sodium Oxybate) and Relexxii® [Methylphenidate Extended-Release (ER) Tablet] – See Appendix N

- A. Current Prior Authorization Criteria
- B. Utilization of ADHD and Narcolepsy Medications
- C. Prior Authorization of ADHD and Narcolepsy Medications
- D. Oklahoma Resources
- E. Market News and Updates
- F. Product Summaries
- G. College of Pharmacy Recommendations
- H. Utilization Details of ADHD and Narcolepsy Medications

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

17. Annual Review of Atypical Antipsychotic Medications and 30-Day Notice to Prior Authorize Abilify Asimtufii® [Aripiprazole Extended-Release (ER) Injection], Quetiapine 150mg Tablet, Rykindo® (Risperidone ER Injection), and Uzedy™ (Risperidone ER Injection) – See Appendix O

- A. Current Prior Authorization Criteria
- B. Utilization of Atypical Antipsychotic Medications
- C. Prior Authorization of Atypical Antipsychotic Medications
- D. Oklahoma Resources
- E. Market News and Updates
- F. Cost Comparison: Aripiprazole Long-Acting Injectable (LAI) Products
- G. Cost Comparison: Quetiapine Products
- H. Cost Comparison: Risperidone LAI Products
- I. College of Pharmacy Recommendations
- J. Utilization Details of Atypical Antipsychotic Medications

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

18. 30-Day Notice to Prior Authorize Daybue™ (Trofinetide) – See Appendix P

- A. Introduction
- B. Daybue™ (Trofinetide) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Reynolds, Dr. Muchmore, Chairman:

19. Annual Review of Muscle Relaxant Medications and 30-Day Notice to Prior Authorize Lyvispah™ (Baclofen Oral Granules), Norgesic®, Norgesic® Forte, and Orphengesic® Forte (Orphenadrine/Aspirin/Caffeine) – See Appendix Q

- A. Current Prior Authorization Criteria
- B. Utilization of Muscle Relaxant Medications
- C. Prior Authorization of Muscle Relaxant Medications

- D. Market News and Updates
- E. Product Summaries
- F. College of Pharmacy Recommendations
- G. Utilization Details of Muscle Relaxant Medications

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

20. Annual Review of Various Special Formulations and 30-Day Notice to Prior Authorize Allopurinol 200mg Tablet, Aponvie™ (Aprepitant Injectable Emulsion), Aspruzyo Sprinkle™ [Ranolazine Extended-Release (ER) Granules], Austedo® XR (Deutetrabenazine ER Tablet), Entadfi® (Finasteride/Tadalafil Capsule), Ermeza™ (Levothyroxine Oral Solution), Furoscix® (Furosemide On-Body Infusor), Iyuzeh™ (Latanoprost Ophthalmic Solution), Jylamvo® (Methotrexate Oral Solution), Primidone 125mg Tablet, Verkazia® (Cyclosporine Ophthalmic Solution), Xaciato™ (Clindamycin Vaginal Gel), and Zolpidem 7.5mg Capsule – See Appendix R

- A. Current Prior Authorization Criteria
- B. Utilization of Various Special Formulations
- C. Prior Authorization of Various Special Formulations
- D. Market News and Updates
- E. Product Summaries
- F. College of Pharmacy Recommendations
- G. Utilization Details of Various Special Formulations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

21. 30-Day Notice to Prior Authorize Joenja® (Leniolisib) – See Appendix S

- A. Introduction
- B. Joenja® (Leniolisib) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

22. Annual Review of Ryplazim® (Plasminogen, Human-tvmh) – See Appendix T

- A. Current Prior Authorization Criteria
- B. Utilization of Ryplazim® (Plasminogen, Human-tvmh)
- C. Prior Authorization of Ryplazim® (Plasminogen, Human-tvmh)
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Reynolds, Dr. Muchmore, Chairman:

23. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix U

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

24. Future Business* (Upcoming Product and Class Reviews)

- A. Allergen Immunotherapies
- B. Alzheimer's Disease Medications

C. Colorectal Cancer Medications

D. Testosterone Products

*Future product and class reviews subject to change.

25.Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.